Whatis

AELMHU?

We are a non-profit association made up of pharmaceutical companies, specialised in rare diseases, that are committed to discovering, researching, developing and commercialising innovative therapies that improve the lives of patients and their families.

AccessReport

AELMHU prepares, on a quarterly and annual basis,
reports on access to orphan drugs in Spain.

Check the latest update

NEWS

NEWS

weber_book_cover_web_01@2x

The social value of orphan drugs

With the aim of highlighting the benefits of orphan therapies, not only for patients and their families, but also in economic terms for the health system, the document "Differential aspects of orphan therapies" has been presented in ... Read more


Clinical Trials Report
in Spain for 2025


AELMHU at PERTE for
Vanguard Health


II Training day for journalists on rare diseases


AELMHU within the Strategic Plan of
Pharmaceutical Industry

AELMHU's contributions to the new public consultation of the Ministry of Health.

AELMHU's contributions to the new public consultation of the Ministry of Health.

Assessments and proposals for access to orphan drugs in Spain.

Assessments and proposals for access to orphan drugs in Spain.

photo-RYM (1)

ARTICLES

History, current situation and future perspectives of neonatal screening for rare diseases in Spain

History, current situation and future perspectives of neonatal screening for rare diseases in Spain
photo 1

INTERVIEWS

Interview with Dr. Montserrat Morales, Coordinator of the Adult Unit for Rare Diseases and Inborn Errors of Metabolism at the Hospital Universitario 12 de Octubre in Madrid.

Interview with Dr. Montserrat Morales, Coordinator of the Adult Unit for Rare Diseases and Inborn Errors of Metabolism at the Hospital Universitario 12 de Octubre in Madrid.

INTERVIEWS



Sickle Cell Disease Day


Life with
Myasthenia

ASSOCIATED COMPANIES

RESEARCH AND COMMITMENT to rare diseases

MEMBERS

Do you want to be part of AELMHU?

What is an orphan drug?

Orphan drugs ( ODM) are innovative treatments, many of them of biotechnological origin, intended to establish a diagnosis, prevent or treat patients with rare or minority diseases for which there is no therapeutic alternative.

NEWSLETTER

Consent(Required)
(Required)
This field is a validation field and must remain unchanged.

  • AELMHU
  • C/ Paseo de la Castellana, 135 7th Floor 28046 Madrid
  • C/ Muntaner, 292, 1º 2ª
  • 08021 Barcelona

Subscribesubscribe to the

AELMHUNEWSLETTER

Consent(Required)
(Required)
This field is a validation field and must remain unchanged.

© 2021
Asociación Española de Laboratorios de Medicamentos Huérfanos y Ultrahuérfanos (Spanish Association of Orphan and Ultra Orphan Drug Laboratories)